There are currently 4 studies (Matulonis et al[15], Martin et al[8], Moore et al[16], Gilbert et al[17]) of focus on the efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer expressing FRα (Table 1). This evidence concerns the gene FOLR1 and ovarian cancer.